ArticleTherapeutic advances in medical oncology2025
Impact of additional cytogenetic aberrations at diagnosis of chronic phase chronic myeloid leukemia.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the correlation between additional cytogenetic abnormalities (ACAs) at diagnosis and their clinical consequences in 337 Chinese chronic myeloid leukemia (CML) patients. Design: Retrospective observational cohort study. Methods: Response criteria were applied according to the European LeukemiaNet. Event-free survival (EFS) and progression-free survival (PFS) were analyzed. Independent predictors of PFS were assessed using Cox regression analysis. Results: At diagnosis, ACAs were identified in 41 patients (12.2%), with 24 exhibiting high-risk ACAs. Patients with high-risk ACAs showed significantly lower molecular response rates than those with low-risk ACAs or non-ACAs. Furthermore, patients with high-risk ACAs demonstrated diminished EFS (45.8% vs 76.5% vs 78.0%, respectively, Conclusion: These findings underscore the importance of integrating cytogenetics-based risk assessments into CML management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.